Case Report An abdominal mass was incidentally found by abdominal echography in a 61-year-old otherwise healthy woman during a routine physical checkup in December 2010. Subsequent abdominal computed tomography (CT) revealed a multilobulated heterogeneously enhanced mass measuring 8.2 5.6 cm in the lower abdomen with several nodules of various sizes in the peritoneum, suggesting peritoneal seeding. Multiple nodules with ring enhancement were detected in both lobes of the liver, suggesting metastasis. In addition, needle biopsy of the liver and histologic examination of the biopsied specimen revealed spindle cell tumor with positive immunostaining of CD117, confirming the diagnosis of metastatic GI stromal tumor (GIST). Tumor DNA amplified by polymerase chain reaction revealed a c-kit mutation consisting of a deletion mutation at codons 553 to 558 in exon 11. The patient received therapy with four 100-mg capsules of imatinib daily in January 2011. After 3 months of treatment, partial response was documented, as assessed by dynamic CT. At 6 months, however, the patient complained of bone pain in both lower extremities, with a limping gait and limited range of motion. A wholebody bone scan using 740 MBq (20 mCi) Tc-99m methylenediphosphonate (Siemens E-Cam Dual Head Gamma Camera, Siemens, Malvern, PA) revealed heterogeneously increased radioactivity uptake along bilateral proximal tibiae (metabolic ratio of tibia to femur, 1.56; Fig 1A), which was compatible with bone infarct. Magnetic resonance imaging was performed on a 3 T scanner (Siemens Tim Trio, Siemens) with unenhanced coronal spin-echo T1weighted images (repetition time [TR], 600 milliseconds; echo time [TE], 16 milliseconds), followed by short inversion time inversion recovery (STIR) images (TR, 6,060 milliseconds; TE, 62 milliseconds; inversion time, 150 milliseconds). STIR images revealed intramedullary heterogenous signal intensity at bilateral tibial diaphysis with serpiginous shape and abnormal enhancement suggesting osteonecrosis (ON; Fig 2A). CoronalT1-weightedmagneticresonanceimagewithfatsuppressionshowed intenseenhancementof the intramedullary lesioninbilateral tibialdiaphysis (Fig 2B). Follow-up coronal T1-weighted magnetic resonance image with fat suppression showed mild decreased enhancement of the intramedullary lesion in bilateral tibial diaphysis (Fig 2C).
[1]
Y. Jan,et al.
Imatinib Mesylate for Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors Expressing KIT: A Decade Experience from Taiwan.
,
2011,
Translational oncology.
[2]
Heikki Joensuu,et al.
Practical management of tyrosine kinase inhibitor-associated side effects in GIST.
,
2011,
Cancer treatment reviews.
[3]
B. Chrcanovic,et al.
Osteoradionecrosis of the jaws—a current overview—part 1
,
2010,
Oral and Maxillofacial Surgery.
[4]
C. Antonescu,et al.
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
,
2009,
The Lancet.
[5]
Hiroaki Nakamura,et al.
Imatinib mesylate suppresses bone metastases of breast cancer by inhibiting osteoclasts through the blockade of c‐Fms signals
,
2009,
International journal of cancer.
[6]
A. Brunello,et al.
Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma.
,
2009,
Bone.
[7]
M. Siddiqui,et al.
Imatinib
,
2012,
Drugs.
[8]
M. Kunkel,et al.
Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis
,
2007,
Supportive Care in Cancer.
[9]
C. Langer.
Osteonecrosis of the jaw, a recently recognized sequela of bisphosphonate therapy: case report.
,
2006,
Supportive cancer therapy.
[10]
A. Saifuddin,et al.
MRI of osteonecrosis.
,
2004,
Clinical radiology.
[11]
L. Assael.
New foundations in understanding osteonecrosis of the jaws.
,
2004,
Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.
[12]
J. Ford,et al.
Practical management of patients with chronic myeloid leukemia receiving imatinib.
,
2003,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13]
A. D. Van den Abbeele,et al.
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
,
2002,
The New England journal of medicine.